Various healthcare companies are already implementing high-tech solutions into existing healthcare systems.
The Phase 3 data presented at AAD include a comprehensive review of the THRIVE-AA2 results and further elaborate the topline data reported in August 2022
Mindset disagrees with and denies the allegations set forth from Reunion.
A funding to expand operations and provide better patient care
Dr. Hubbard brings more than 35 years of experience in the biopharmaceutical and pharma-tech services industries and CROs.
Chronic Kidney Disease is a growing epidemic with 850 million people affected worldwide.
Time to combine innovation, access and technology to deliver positive patient outcomes
Company will invest in capacity increases, technological capabilities and long-term partnerships with key pharmaceutical and biotech companies
The Development Center with its state-of-the art laboratories and flexible pilot capacities is set to become Siegfried's global research and development hub for its Drug Products sites, strengthening the global network
Based on this inspection and the USFDA VAI classification, this facility is in compliance with regard to current good manufacturing practices (cGMP)
Subscribe To Our Newsletter & Stay Updated
